Interleukin-2 receptor antagonist induction in modern immunosuppression regimens for renal transplant recipients

被引：24
作者：
Vincenti, Flavio
de Andres, Amado
Becker, Thomas
Choukroun, Gabriel
Cole, Edward
Gonzalez-Posada, Jose M.
Kumar, Mysore A.
Moore, Richard
Nadalin, Silvio
Nashan, Bjorn
Rostaing, Lionel
Saito, Kazuhide
Yoshimura, Norio
机构：
[1] Univ Calif San Francisco, Transplant Serv, San Francisco, CA 94143 USA
[2] Hosp Univ 12 Octubre, Unidad Transplantat Renal, Madrid, Spain
[3] Hannover Med Sch, Klin Transplantat Chirurg, Hannover, Germany
[4] CHU Amiens, Hop Sud, Dept Nephrol, Amiens, France
[5] Univ Toronto, Renal Transplant Program, Toronto, ON, Canada
[6] Hosp Univ Canarias, Undad Coordinadora Transplantes, Tenerife, Spain
[7] Med Coll Penn & Hahnemann Univ, Div Transplantat, Philadelphia, PA 19102 USA
[8] Univ Wales Hosp, Renal Unit, Cardiff, Wales
[9] Univ Klinikum Essen, Klin Allgemein & Tranplantat Chirurg, Essen, Germany
[10] QEII Hlth Sci Ctr, Multiorgan Transplant Program, Halifax, NS, Canada
[11] Univ Hosp Rangueil, Serv Nephrol, Toulouse, France
[12] Niigata Univ, Grad Sch Med & Dent Sci, Div Urol, Niigata, Japan
[13] Kyoto Prefectural Univ Med, Dept Transplantat, Kyoto, Japan
来源：
TRANSPLANT INTERNATIONAL | 2006年 / 19卷 / 06期
关键词：
basiliximab; daclizumab; interleukin-2; interleukin-2 receptor antagonist; rabbit antithymocyte globulin; thymoglobulin;
D O I：
10.1111/j.1432-2277.2006.00321.x
中图分类号：
R61 [外科手术学];
学科分类号：
摘要：
Addition of interleukin-2 receptor antagonist (IL-2RA) induction to calcineurin inhibitor (CNI)-based regimens reduces biopsy-proven acute rejection by 30-40%. IL-2RA induction facilitates early withdrawal of steroids, and supports the safe use of reduced-exposure CNI or delayed CNI introduction. IL-2RAs and rabbit antithymocyte globulin (Thymoglobulin((R))) show comparable efficacy in patients at standard or low immunologic risk, but the adverse event profiles of lymphocyte-depleting agents are less favorable. IL-2RAs, uniquely, provide effective immunosuppression with similar tolerability to placebo.
引用
收藏
页码：446 / 457
页数：12
相关论文
共 57 条
[1]   Interleukin-2 receptor monoclonal antibodies in renal transplantation: meta-analysis of randomised trials [J].
Adu, D ;
Cockwell, P ;
Ives, NJ ;
Shaw, J ;
Wheatly, K .
BRITISH MEDICAL JOURNAL, 2003, 326 (7393) :789-791
[2]   PROLONGED ACTION OF A CHIMERIC INTERLEUKIN-2 RECEPTOR (CD25) MONOCLONAL-ANTIBODY USED IN CADAVERIC RENAL-TRANSPLANTATION [J].
AMLOT, PL ;
RAWLINGS, E ;
FERNANDO, ON ;
GRIFFIN, PJ ;
HEINRICH, G ;
SCHREIER, MH ;
CASTAIGNE, JP ;
MOORE, R ;
SWENY, P .
TRANSPLANTATION, 1995, 60 (07) :748-756
[3]  
Andres A, 2005, AM J TRANSPLANT, V5, P570
[4]   Inhibition of the IL-15 pathway in anti-CD25 mAb treated renal allograft recipients [J].
Baan, CC ;
van Riemsdijk-Overbeeke, IC ;
Boelaars-van Haperen, MJAM ;
IJzermans, JMN ;
Weimar, W .
TRANSPLANT IMMUNOLOGY, 2002, 10 (01) :81-87
[5]   Monoclonal antibody basiliximab with low cyclosporine dose as initial immunosuppression [J].
Boletis, JN ;
Theodoropoulou, H ;
Hiras, T ;
Stamatiadis, D ;
Darema, M ;
Psimenou, E ;
Stathakis, C ;
Kostakis, A .
TRANSPLANTATION PROCEEDINGS, 2001, 33 (7-8) :3184-3186
[6]  
BRENNAN DC, 2003, AM J TRANSPLANT S4, V76, P438
[7]  
Chao AB, 2005, AM J TRANSPLANT, V5, P402
[8]   Basifiximab - A review of its use as induction therapy in renal transplantation [J].
Chapman, TM ;
Keating, GM .
DRUGS, 2003, 63 (24) :2803-2835
[9]   Association of the type of induction immunosuppression with posttransplant lymphoproliferative disorder, graft survival, and patient survival after primary kidney transplantation [J].
Cherikh, WS ;
Kauffman, HM ;
McBride, MA ;
Maghirang, J ;
Swinnen, LJ ;
Hanto, DW .
TRANSPLANTATION, 2003, 76 (09) :1289-1293
[10]   A pilot study of steroid-free immunosuppression in the prevention of acute rejection in renal allograft recipients. [J].
Cole, E ;
Landsberg, D ;
Russell, D ;
Zaltzman, J ;
Kiberd, B ;
Caravaggio, C ;
Vasquez, AR ;
Halloran, P .
TRANSPLANTATION, 2001, 72 (05) :845-850
123456